Altair Nanotechnologies Inc (ALTI) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2009

Altair Nanotechnologies Inc

CIK: 1016546 Ticker: ALTI

Altair Nanotechnologies Reports 2009 Financial Results

RENO, Nev. – March 11, 2010 – Altair Nanotechnologies, Inc. (Altairnano) (Nasdaq: ALTI), a provider of energy storage systems for clean, efficient power and energy management, today reported financial results for the year ended December 31, 2009.

For the year ended December 31, 2009, the Company reported revenues of $4.4 million, down from $5.7 million for 2008.  The net loss was $21.9 million, or 21 cents per share, compared to a net loss of $29.3 million, or 34 cents per share, for 2008. The basic and diluted weighted average shares outstanding for the year were 100.2 million, compared to 85.9 million reported in 2008.

Operating expenses of $27.2 million for 2009 were $8.7 million less than the operating expenses of $35.9 million for 2008.  The 2008 results contained several one-time expenses including the settlement expense of $3.6 million with Al Yousuf LLC, the reversal of $2.9 million in warranty expense and the forgiveness of $1.7 million in notes receivable associated with resolution of the various Phoenix Motor Cars issues.  Similarly, 2009 contains the one-time impairment loss on the AlSher assets of $1.3 million.  Even adjusting for all of these one-time items, the 2009 operating expense reduction from 2008 was $7.6 million consisting primarily of the elimination of R&D expenditures of $6.6 million as we eliminated activities in the former Life Sciences and Performance Materials divisions. In addition we had a reduction in G&A expenses of $1.6 million resulting from a number of different initiatives.

The Company’s cash and cash equivalents decreased by $10.0 million, from $28.1 million at December 31, 2008 to $18.1 million at December 31, 2009. This is due primarily to net cash used in operations of approximately $23.6 million, $4.9 million of which was for increased product inventories; investing activities primarily consisting of purchases of fixed assets of approximately $0.8 million offset by $2.0 million received from the sale of our Spectrum common stock; and financing activities that include payment of notes payable of $0.6 million offset by $12.8 million of proceeds relating to the issuance of common shares in May 2009.

The Company’s monthly cash burn rate has been higher throughout 2009 than it was in the second half of 2008 as the Company has been building up inventory of component parts with three to six month lead times in anticipation of sales in early 2010. If sales in early 2010 do not materialize, we expect our cash burn rate to slow as the Company believes it now has adequate levels of components in inventory.  Product inventories are higher by $4.9 million and prepaid expenses by $1.2 million from their respective December 31, 2008 balances.  The increase in prepaid expenses results largely from a partial payment on the purchase of battery cells from the Company’s Korean cell manufacturer.

“We continue to position the company to take advantage of the opportunities we see developing throughout 2010,” said Dr. Terry Copeland, Altairnano’s president and CEO. “Discussions with potential customers continue to advance and we expect order activity to gain traction in our key market segments. We have begun to build inventory levels in order to move expeditiously once we have these initial firm orders.”

During 2009 Altairnano completed work on the Office of Naval Research phase 1 development program, received the final signed contracts for both the $3.8 million Office of Naval Research phase 2 development program, and the Department of Defense supported $1.8 million nanosensor project.  Although work on both of these projects began in 2009, the Company will continue that work during the first half of 2010.

Page 2

During 2009 Altairnano reached agreement with Spectrum to modify its existing contract to assign ownership of all patent rights associated with RenazorbTM and RenalanTM compounds to Spectrum.  Under the terms of the agreement, the Company received $750,000 in Spectrum restricted common stock and a right to future royalties and milestone payments upon completion of certain specified events.  The Company is also currently in negotiations with Sherwin-Williams to potentially sell our interest in the AlSher Titania joint venture to them, thus enabling Altairnano to exit the performance materials arena as it already has the life sciences arena.

Year End 2009 Conference Call
Altairnano will hold a conference call to discuss its 2009 results on Thursday, March 11, 2010 at 11:00 a.m. Eastern Standard Time (EST). Shareholders and members of the investment community are invited to participate in the conference call. The dial-in number for both U.S. and international callers is +1 678-224-7719. Please dial in to the conference five minutes before the call is scheduled to begin. Ask the operator for the Altair Nanotechnologies call.
An audio replay of the conference call will be available from 2:00 p.m. EST, Thursday, March 11, until Midnight EST, April 10, 2010. It can be accessed by dialing +1 706-645-9291 and entering conference number 60968372.
Additionally, the conference call and replay will be available online, and can be accessed by visiting Altairnano's web site,
About Altair Nanotechnologies, Inc.
Headquartered in Reno, Nevada with manufacturing in Anderson, Indiana, Altairnano is a leading provider of energy storage systems for clean, efficient power and energy management. Going beyond lithium ion, Altairnano's Lithium-Titanate based battery systems are among the highest performing and most scalable, with applications that include battery cells for military artillery, battery packs for hybrid vehicles and energy storage systems for large-scale stationary power services. For more information please visit Altairnano at
Forward-Looking Statements
This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause Altairnano’s actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that development of any the early-stage products of the Company will not be completed for technical, business or other reasons; that any products under development or in the early commercial stages will not perform as expected in future testing or commercial applications; that customers or prospective customers will not use or purchase products as represented to us or otherwise expected for various reasons, including a buyer’s purchasing of a competing product, absence of agreement over pricing or a buyer’s absence of capital to purchase products; that one or more of the joint development partners or customers may proceed slowly with, or abandon, development or commercialization efforts for any of various reasons, including concerns with the feasibility of the product or the financial viability of continuing with our products or their product; that sales of commercialized Altairnano products may not reach expected levels for one or more reasons, including the failure of end products to perform as expected or the introduction of a superior product; that costs associated with the proposed products may exceed revenues; and that, due to unexpected expenses not accompanied by offsetting revenue, the Company’s use of cash in its operations may exceed budgeted levels.  In general, Altairnano is, and expects to be in the immediate future, dependent upon funds generated from sales of securities, grants, testing agreements, and licensing agreements to fund its testing, development and ongoing operations. In addition, other risks are identified in the Company's most recent Annual Report on Form 10-K filed with the SEC. Such forward-looking statements speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in Company expectations or results or any change in events.


Page 3
For Additional Information:

Institutional Investors:                                            
Brion D. Tanous
CleanTech IR, Inc.                                                    

Individual Investors:
Tom Herbert
CleanTech IR, Inc.    

Media Relations:
Jeff Brunings
Director, Strategic Marketing
Altair Nanotechnologies, Inc.
Tables Follow

Page 4
(Expressed in thousands of United States Dollars, except shares and per share amounts)
December 31,
December 31,
Current Assets
Cash and cash equivalents
  $ 18,122     $ 28,088  
Investment in available for sale securities
    505       -  
Accounts receivable
    683       955  
Product inventories
    5,043       98  
Prepaid expenses and other current assets
    1,820       572  
Total current assets
    26,173       29,713  
Investment in available for sale securities
    2,587       3,174  
Property, plant and equipment, net held and used
    8,670       11,637  
Property, plant and equipment, net held and not used
    2,211       2,377  
Patents, net
    551       636  
Other assets
    125       534  
Total Assets
  $ 40,317     $ 48,071  
Current Liabilities
Trade accounts payable
  $ 1,783     $ 749  
Accrued salaries and benefits
    625       1,361  
Accrued warranty
    79       36  
Accrued liabilities
    758       765  
Note payable, current portion
    794       732  
Capital lease obligation – current portion
    16       4  
Total current liabilities
    4,055       3,647  
Capital lease obligation, less current portion
    37       608  
Total Liabilities
    4,092       4,255  
Stockholders' Equity
Common stock, no par value, unlimited shares authorized;
105,400,728 and 93,143,271 shares issued and
outstanding at December 31, 2009 and December 31, 2008
    188,515       180,105  
Additional paid in capital
    10,933       5,378  
Accumulated deficit
    (162,204 )     (140,892 )
Accumulated other comprehensive loss
    (1,560 )     (1,873 )
Total Altair Nanotechnologies Inc.’s Stockholders' equity
    35,684       42,718  
Noncontrolling Interest in Subsidiary
    541       1,098  
Total Liabilities and Stockholders' Equity
  $ 40,317     $ 48,071  

Page 5

(Expressed in thousands of United States Dollars, except shares and per share amounts)
Year Ended December 31,
Product sales
  $ 945     $ 757     $ 4,058  
Less: Sales returns
    (184 )     -       -  
License fees
    750       -       -  
Commercial collaborations
    1,410       2,007       2,910  
Contracts and grants
    1,450       2,962       2,140  
Total revenues
    4,371       5,726       9,108  
Operating Expenses
Cost of sales – product
    954       183       5,164  
Cost of sales – warranty and inventory reserves
    198       (2,865 )     6,843  
Research and development
    10,323       16,908       15,444  
Sales and marketing
    2,819       2,950       2,001  
Notes receivable extinguishment
    -       1,722       -  
Settlement and release
    -       3,605       -  
Asset impairment
    1,308       -       -  
General and administrative
    8,943       10,590       10,770  
Depreciation and amortization
    2,687       2,759       1,954  
Total operating expenses
    27,232       35,852       42,176  
Loss from Operations
    (22,861 )     (30,126 )     (33,068 )
Other Income (Expense)
Interest expense
    (107 )     (97 )     (134 )
Interest income
    188       982       1,101  
Realized gain/(loss) on investment
    851       (89 )     -  
Loss on foreign exchange
    (2 )     (10 )     (1 )
Total other income, net
    930       786       966  
Net Loss
    (21,931 )     (29,340 )     (32,102 )
Less:  Net loss attributable to non-controlling interests
    619       272       631  
Net Loss Attributable to Altair Nanotechnologies Inc.
  $ (21,312 )   $ (29,068 )   $ (31,471 )
Loss per common share - Basic and diluted
  $ (0.21 )   $ (0.34 )   $ (0.45 )
Weighted average shares - Basic and diluted
    100,177,727       85,903,712       71,008,505  


The following information was filed by Altair Nanotechnologies Inc (ALTI) on Thursday, March 11, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Altair Nanotechnologies Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Altair Nanotechnologies Inc.


Assess how Altair Nanotechnologies Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Altair Nanotechnologies Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2010 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Altair Nanotechnologies Inc provided additional information to their SEC Filing as exhibits

Ticker: ALTI
CIK: 1016546
Form Type: 10-K Annual Report
Accession Number: 0001019687-10-000940
Submitted to the SEC: Thu Mar 11 2010 9:35:14 PM EST
Accepted by the SEC: Fri Mar 12 2010
Period: Thursday, December 31, 2009
Industry: Miscellaneous Chemical Products

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: